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Simple Summary: Targeting topoisomerases has been widely used as anticancer therapeutics. Expo-
sure to high temperature (hyperthermia) protects cells from the cytotoxic effect of topoisomerase-
targeting therapeutics, yet the mechanism remains unknown. Here, we report that hyperthermia
inhibits the nucleolytic processing of topoisomerase-induced DNA damage and drives repair to a
more faithful pathway mediated by TDP1 and TDP2. We further show that hyperthermia suppresses
topoisomerase-induced chromosomal translocation and hallmarks of inflammation, which has broad
implications in cancer development and therapy.
Abstract: Cancer-causing mutations often arise from inappropriate DNA repair, yet acute exposure
to DNA damage is widely used to treat cancer. The challenge remains in how to specifically induce
excessive DNA damage in cancer cells while minimizing the undesirable effects of genomic instability
in noncancerous cells. One approach is the acute exposure to hyperthermia, which suppresses DNA
repair and synergizes with radiotherapy and chemotherapy. An exception, however, is the protective
effect of hyperthermia on topoisomerase targeting therapeutics. The molecular explanation for this
conundrum remains unclear. Here, we show that hyperthermia suppresses the level of topoisomerase
mediated single- and double-strand breaks induced by exposure to topoisomerase poisons. We
further uncover that, hyperthermia suppresses hallmarks of genomic instability induced by topoiso-
merase targeting therapeutics by inhibiting nuclease activities, thereby channeling repair to error-free
pathways driven by tyrosyl-DNA phosphodiesterases. These findings provide an explanation for
the protective effect of hyperthermia from topoisomerase-induced DNA damage and may help to
explain the inverse relationship between cancer incidence and temperature. They also pave the way
for the use of controlled heat as a therapeutic adjunct to topoisomerase targeting therapeutics.
Keywords: topoisomerase; TDP1; TDP2; cancer; ageing; hyperthermia; genomic instability
1. Introduction
Cancer is a leading cause of mortality with variable incidence among populations [1].
Analysis of epidemiological data has uncovered an inverse pattern of geographical cancer
distribution and annual temperature. Countries with low average annual temperatures
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exhibit the highest incidence of cancer [1–4]. The two populations living in the coldest
environments, Alaska Indians and Inuit, exhibit high cancer incidence [3,5]. Although
human thermoregulation systems sustain body core temperature at 37 ◦C, exposure to
extreme or sustained temperatures overwhelms the body’s thermoregulatory capacity
especially at old age, leading to hypothermia (<35 ◦C) or hyperthermia (>40.5 ◦C) [6,7].
How the changes in environmental and body temperature affect cancer development
remains unclear.
Hyperthermia treatment, also known as thermotherapy, is an ancient treatment used to
treat cancer, dating back to 5000 BC [8]. Thermotherapy is applied by regionally heating the
tumor to 40–45 ◦C [9,10]. Hyperthermia induces a wide range of cellular effects, including
mitotic dysfunction, cytoskeletal damage, alternations in membrane structure, metabolic
dysfunction, DNA damage, interference with cell cycle, and protein denaturation [9,11,12].
While noncancerous cells can tolerate temperature up to 42–45 ◦C, cancerous cells are
more susceptible [13–15]. Hyperthermia enhances the effectiveness of radiotherapy and
chemotherapy, including cisplatin, carboplatin, cyclophosphamide, ifosfamide, melphalan,
mitomycin C, and histone deacetylase inhibitors [10,16–19]. A well-studied example is the
synergistic effect of hyperthermia with radiation therapy (thermo-radiosensitization) [20].
Thermo-radiosensitization was shown to be due to increased tumor oxygenation uptake
through enhancing blood flow, which overcomes radiation resistance to hypoxia [10].
Hyperthermia has also been shown to increase radiation-induced double-strand breaks
(DSBs) [21,22], through heat-mediated inactivation of the DSB repair pathways, non-
homologous end joining (NHEJ) and homologous recombination (HR) [19,23–26].
Hyperthermia inhibits several DNA repair pathways, including components of the
DNA base excision repair (BER), nucleotide excision repair (NER), mismatch repair (MMR),
single-strand breaks (SSBs) repair, and DSB repair pathways [19,27]. Moreover, hyperther-
mia induces DNA damage directly, whereby increased levels of 8-oxoguanine, apurinic
sites, and deaminated cytosines were identified following heat exposure [9,27–29]. While
hyperthermia increases DSB formation, this effect was explained as an indirect conse-
quence of interfering with DNA repair mechanisms [9,27,28,30]. Hyperthermia has also
been shown to inhibit HR by triggering BRCA2-degradation [23,25,26], which opened new
avenues for combination therapies with PARP inhibitors, specifically targeting HR-deficient
tumors [31,32].
In contrast to radiation and several chemotherapeutic agents, hyperthermia failed to
sensitize cells to topoisomerase (TOP) inhibitors and instead exerted a protective effect.
This paradigm remains unexplained [33–36]. Topoisomerases remove topological stress
by cleaving and resealing DNA strands. This mode of catalysis can be dangerous if
topoisomerases become covalently linked to DNA, generating an intermediate known as
topoisomerase cleavage complex (TOPcc). While TOPcc is reversible, it can be trapped by
topoisomerase poisons such as camptothecin and etoposide, targeting TOP1 and TOP2,
respectively, and becomes an irreversible DNA–protein crosslink (DPC). DPC interferes
with replication and transcription, leading to genome instability or cell death [37–39].
Accumulation of TOP-DNA breaks is counteracted by repair factors that precisely disjoin
the covalently linked topoisomerases from DNA through the activity of tyrosyl-DNA
phosphodiesterases (TDP1 and TDP2), or nucleolytically cleave the DNA, releasing the
topoisomerases and a fragment of DNA [37–40]. The cell’s decision to choose TDPs or
nucleases has important consequences on genome stability as TDPs spare the genome
from error-prone nucleolytic cleavage [37–43]. Notably, mutations in genes encoding
the TDP proteins lead to neurodegenerative conditions [44–46]. Several nucleases are
implicated in DPC repair, such as CtIP and MRE11, which participate in processing TOP1cc
and TOP2cc, while the structure-specific nucleases, MUS81–EME1 and XPF–ERCC1, are
primarily implicated in processing TOP1cc [37–39].
The inappropriate error-prone repair of topoisomerase-induced DNA breaks has been
associated with cancer, neurodegenerative disease, and autoimmune syndromes [37,47–50].
The association between topoisomerases and cancer is best illustrated by the role of TOP2cc
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in inducing chromosomal translocations. This association was first established by the
observation that cancer-targeting TOP2 inhibitors develop secondary leukemia by inducing
MLL and PML-RARA translocation [37,49,51]. Moreover, androgen signaling co-recruits
androgen receptor and TOP2β to TMPRSS2 and ERG genes. The recruited TOP2β induces
de novo TMPRSS2-ERG fusion, resulting in prostate cancer development [52]. Chromosome
loop anchors, bound by CTCF and cohesion, were shown to be vulnerable to DSBs mediated
by TOP2β, leading to chromosomal rearrangements. The kinetics of TOP2β-mediated
translocation can be predicted by cohesin and transcription levels at particular sites [43,53].
Another report has shown that damaged introns with paused RNA pol II, TOP2β, and
XRCC4 are enriched in translocation breakpoints [54]. Consistently, the TOP2 inhibitor,
etoposide, induces high levels of chromosomal translocations in cells deficient for the TOP2-
DNA repair enzyme, TDP2 [41,42]. Translocations that arise in the absence of TDP2 are
most likely mediated by a mutagenic DSB repair mechanism that employs endonucleases
such as MRE11 [41,42,49,55]. Another link was established between TOPcc and cancer,
where TOP1 was shown to mediate a mutagenic pathway to remove ribose contamination
from DNA. This unfaithful role has been implicated in 5 bp deletions in highly transcribed
genes and in generating lesions that trap PARP1, leading to cell killing [56–58].
Although the protective effect of hyperthermia on topoisomerase targeting therapeu-
tics has been reported, the underlying molecular mechanism remains unclear. Moreover,
the impact of hyperthermia on topoisomerase-induced genomic instability is unknown.
Here, we report that hyperthermia suppresses the level of topoisomerase mediated single-
and double-strand breaks induced by exposure to topoisomerase poisons. Furthermore,
we uncover that hyperthermia suppresses the level of genomic instability induced by
topoisomerase poisons by inhibiting nuclease activities, thereby channeling repair to the
error-free TDP pathways. These findings identify a novel mechanism for the protective
effect of hyperthermia from topoisomerase-induced genomic instability and could help in
understanding the inverse relationship between cancer and environmental temperature.
2. Results
2.1. Hyperthermia Reduces the Catalytic Activity of TDP1 and TDP2
To test the effect of heating (hyperthermia) on TDP1 catalytic activity, we used an
in vitro biochemical assay employing a single-stranded oligonucleotide substrate con-
taining a 3′-phosphotyrosine (3′P-tyr) and 5′-fluorophore. The cleaved tyrosine from the
substrate leads to faster migration, resulting in a slightly lower molecular weight band,
indicative of TDP1 catalytic activity. RKO cells were exposed to 43 ◦C and whole-cell lysates
were incubated with the TDP1 substrate. Exposure to hyperthermia led to a reduction in
TDP1 catalytic activity, which was significant following 1 h exposure to heat (Figure 1a).
We also observed that increasing heat exposure time led to a time-dependent reduction
in TDP1 activity. The reduced activity was associated with a corresponding reduction in
TDP1 protein levels (Figure 1b). This effect was not cell-type specific as a similar result
was observed in MCF-7 cells (Supplementary Figure S1a) and remained apparent after
recovery from heat exposure up to 12 h (Supplementary Figure S1b). Notably, inhibiting
the proteasome by MG132 treatment exacerbated the inhibitory effect of hyperthermia on
TDP1 catalytic activity and the reduction in TDP1 protein level (Figure 1b,c). This effect
was not due to an impact of MG132 on TDP1 transcript levels (Supplementary Figure S1c).
It was specific to MG132 as inhibitors for PARP1, ATM/ATR, ubiquitin isopeptidases,
and HSP90 did not result in a similar effect (Figure 1d). The synergistic effect of MG132
on hyperthermia-induced suppression of TDP1 activity is in contrast to the rescue of
hyperthermia-induced proteasome degradation reported for other DNA repair proteins
such as BRCA2 [23].
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Figure 1. Hyperthermia reduces TDP1 activity. (a) RKO cells were incubated for the indicated time at 43 ◦C. Then, the
cells were collected and lysed. Whole cell lysates (0.2 µg) were incubated for 30 min with TDP1 substrate to monitor
TDP1 catalytic activity in buffer containing EDTA. Reaction products were separated by 20% denaturing PAGE. TDP1
catalytic activity was quantified as % cleavage of 3′P-Tyr to 3′P. (b) TDP1 protein level was determined by Western blot after
incubating the RKO cells with 10 µM MG132 and/or heating at 43 ◦C for the indicated time. (c) RKO cells were treated with
10 µM MG132 and/or heating at 43 ◦C for the indicated time points. TDP1 activity was assessed as in (a). TDP1 activities
were normalized to control (0 h) and presented as relative percentage change. (d) RKO cells were treated with DMSO
(Control), 10 µM proteasomei (MG132), 15 µM PARPi (olaparib), 10 µM ATM/ATRi (CGK733), 5 µM ubiquitin isopeptidasei
I (ubi isoi; G5) or 1.2 µM HSP90i (17-AAG) at 37 ◦C (left) or at 43 ◦C (right) for 3 h. TDP1 activity was assessed as in (a).
Data represent the mean of at least three biological replicates ± SD. Asterisks denote statistical significance (* p < 0.05, and
** p < 0.01 as per Student’s t-test).
We recently reported that TDP1 protein levels are regulated by ubiquitination and
identified the deubiquitinase (DUB), UCHL3, as the DUB regulating TDP1 proteostasis [59].
Therefore, we considered the possibility that hyperthermia reduces UCHL3 levels, which
would increase TDP1 ubiquitination and consequently reduce TDP1 levels. Hyperthermia
exposure led to a reduction in UCHL3 protein levels (Supplementary Figure S1d), which
could partly explain the inhibitory effect of hyperthermia on TDP1 level and activity. How-
ever, this was not sufficient to explain the synergistic effect of hyperthermia and proteasome
inhibition on TDP1, as MG132 treatment did not further reduce the hyperthermia-induced
reduction in UCHL3 levels (Supplementary Figure S1e). In an attempt to identify hyperther-
mia dependent factors that regulate TDP1 levels, we compared TDP1 interactome with and
without exposure to heat stress using mass spectrophotometry. These experiments identi-
fied USP10 as a putative hyperthermia dependent TDP1 partner (Supplementary Table S1).
However, depletion of USP10 did not impact TDP1 activity following exposure to hyper-
thermia (Supplementary Figure S1f,g). A similar approach was also unable to identify
putative proteins responsible for BRCA2 degradation following hyperthermia [23].
We next examined TDP2 activity using in vitro biochemical assays employing double-
stranded oligonucleotide substrate, forming 4 nucleotide overhang similar to TOP2 induced
break and contains a 5′-phosphotyrosine (5′P-tyr) and 3′-fluorophore. Similar to TDP1,
exposure of RKO cells to 43 ◦C led to a reduction in TDP2 catalytic activity, which was
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significant following 1 h exposure to heat (Figure 2a). We also observed that increasing heat
exposure time led to a time-dependent reduction in TDP2 activity. This was also concomi-
tant with a reduction in TDP2 protein level (Figure 2b). MG132 treatment reduced TDP2
activity as hyperthermia (Figure 2c), without a corresponding reduction in TDP2 transcript
levels (Supplementary Figure S1c). Taken together, we conclude that hyperthermia reduces
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Figure 2. Hyperthermia reduces TDP2 activity. (a) RKO cells were incubated for the indicated time at 43 ◦C. Then, the
cells were collected and lysed. Whole cell lysates (15 µg) were incubated with TDP2 substrate for 30 min to monitor TDP2
catalytic activity. Reaction products were separated by 20% denaturing PAGE. TDP2 catalytic activity was quantified as %
cleavage of 5′P-Tyr to 5′P. (b) TDP2 protein level was determined by Western blot after incubating the RKO cells with 10 µM
MG132 and/or heating at 43 ◦C for the indicated time. TDP2 protein levels were normalized to control and presented
as a relative percentage change. (c) RKO cells were treated with DMSO (control), 10 µM proteasomal inhibitor (MG132),
15 µM PARPi (olaparib), 10 µM ATM/ATRi (CGK733), 5 µM ubiquitin isopeptidasei I (ubi isoi; G5) or 1.2 µM HSP90i
(17-AAG) at 37 ◦C or 43 ◦C for 3 h. TDP2 activity was assessed as in (a). Data represent the mean of at least three biological
replicates ± STD. Asterisks denote statistical significance (* p < 0.05, ** p < 0.01 and **** p < 0.0001 as per Student’s t-test).
2.2. Hyperthermia Protects from Topoisomerase-Induced DNA Damage
The hyperthermia-induced reduction in TDP1 and TDP2 level and activities led to
the proposition that hyperthermia could consequently increase topoisomerase-induced
DNA damage. To examine the effect of hyperthermia on topoisomerase-induced DNA
damage, we used TOP poisons, which result in TOP-DNA breaks. To eliminate the potential
effect of hyperthermia on cell cycle, we synchronized wild-type (TK6TDP1+/+) and TDP1
knockout (TK6TDP1-/-) cells in the G1 by double thymidine block and then treated cells
with the TOP1 poison, camptothecin (CPT) and quantified DNA strand breaks by the
comet assay. In contrast to our predictions, pre-exposure of cells to 43 ◦C suppressed
CPT-induced single-strand breaks (SSBs) and double-strand breaks (DSBs), as measured by
the comet assays (Figure 3a,b). The alkaline comet assays measure both SSBs and DSBs,
but primarily SSBs because of their increased abundance relative to DSBs, whereas the
neutral comet assays measure DSBs [44,60]. We noted that, the absence of TDP1 did not
affect the suppression of CPT induced breaks by exposure to hyperthermia. Consistently,
hyperthermia antagonized the cytotoxic effect of CPT in both TK6TDP1+/+ and TK6TDP1-/-
cells, as measured by viability assays (Figure 3c). Notably, our viability data and the
hyperthermia conditions used here are consistent with the published reports showing that
hyperthermia protects cells from the cytotoxic effect of topoisomerase inhibitors [33–36].
The possibility that hyperthermia reduced the formation of TOPcc was excluded since
multiple independent reports have shown that hyperthermia did not reduce the activity
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of TOP1, TOP2 or the level of TOP1cc and TOP2cc [33,35,36]. On the contrary, it has
been suggested that hyperthermia induces the formation of stable TOP1cc during early
S-phase [61]. Consistent with the published literature, we also did not observe a detectable
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Figure 3. Hyperthermia reduces the level of topoisomerase-induced DNA damage through a TDP independent mechanism.
(a,b) G1 synchronized TK6TDP1+/+ and TK6TDP1-/- cells were incubated at 37 or 43 ◦C for 3 h, then 100 µM CPT was added
to the cells for 45 min. DNA breaks, including single and double strand breaks, were quantified by alkaline comet assay (a),
whereas DNA double strand breaks were quantified by the neutral comet assays (b). (c) Short term viability assay was
used to determine the effect of hyperthermia on CPT-induced cytotoxicity. TK6TDP1+/+ and TK6TDP1-/- were incubated at
37 or 43 ◦C for 1 h. Then, CPT was added at the indicated concentration for 1 h, followed by washing the cells with PBS
and keeping the cells in fresh media for 3 days. CellTiter-Blue was used to measure cell viability. (d,e) G1 synchronized
TK6TDP1+/+ and TK6TDP1-/- cells were incubated at 37 or 43 ◦C for 3 h, then 80 µM hydrogen peroxide (H2O2) (d) or 0.075%
tertiary-butylhydroperoxide (TBH) (e) was added to the cells for 30 min. DNA strand breaks were quantified by the alkaline
comet assays. (f) G1 synchronized TK6TDP1+/+ and TK6TDP1-/- cells were incubated at 37 or 43 ◦C for 3 h, then 120 µM
Temozolomide (TMZ) was added to the cells for 12 h. DNA strand breaks were quantified by the alkaline comet assays.
(g,h) G1 synchronized MEFTDP2+/+ and MEFTDP2-/- cells were incubated at 37 or 43 ◦C for 3 h, then 100 µM etoposide (ETO)
was added for 2 h. DNA strand breaks were quantified by the alkaline comet assays (g) or neutral comet (h). (i) Short term
viability assay was used to determine the effect of hyperthermia on ETO-induced cytotoxicity. MEFTDP2+/+ and MEFTDP2-/-
were incubated at 37 or 43 ◦C for 1 h. Then, ETO was added at the indicated concentrations for 1 h, followed by washing
the cells with PBS, and keeping the cells in fresh media for 5 days. CellTiter-Blue was used to measure cell viability. Data
are the average of at least three biological replicates ± SD. Asterisks denote statistical significance (* p < 0.05, ** p < 0.01 and
*** p < 0.001; Student’s t-test).
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We next considered the possibility that heat shock proteins could mediate the protec-
tive effect of hyperthermia. To test this, we quantified DNA strand breaks after exposure
to hyperthermia with and without pretreatment with inhibitors for HSP70 (Pifithrin-µ),
HSP90 (17-AAG) or the proteasome (MG132). None of these inhibitors reversed the protec-
tive effect of hyperthermia on CPT-induced strand breaks (Supplementary Figure S2b–d).
We then wondered whether such a protective effect of hyperthermia applies to other SSB-
inducing agents. To test this, we used hydrogen peroxide and tert-butyl hydroperoxide
(TBH), which are established inducers of oxidative SSBs. Unlike CPT, hyperthermia did
not protect cells from hydrogen peroxide and TBH-induced SSBs (Figure 3d,e). Further-
more, hyperthermia enhanced the level of DNA damage induced by the alkylating agent,
temozolomide (Figure 3f). These results suggest that the protective effect of hyperthermia
is specific to topoisomerase poisons. To test if this is also the case for TOP2 mediated
DNA damage, we synchronized wild-type (MEFTDP2+/+) and TDP2 knockout (MEFTDP2-/-)
mouse embryonic fibroblasts in G1 and exposed cells to the TOP2 inhibitor, etoposide.
Pre-exposure to 43 ◦C also suppressed etoposide-induced SSBs and DSBs in both cell
lines (Figure 3g,h). Consistently, hyperthermia protected both cell lines from cell death
induced by etoposide, as measured by viability assays (Figure 3i). Taken together, we
conclude that hyperthermia suppresses topoisomerase-induced DNA damage through a
TDP-independent mechanism.
2.3. Hyperthermia Favors an Error-Free Repair for Topoisomerase-Induced DNA Damage
The above comet results have shown that hyperthermia decreases the amount of
TOP-induced DNA damage in a TDP-independent manner. Yet, the fate of the remaining
DNA damage following hyperthermia remains unclear. Trapped topoisomerases can
be removed by one of two alternative pathways, TDPs or nucleases. The heat-induced
reduction in the activity and level of TDPs (Figures 1 and 2) suggests that the nuclease
pathway is likely responsible for processing the remaining TOP-induced DNA damage. To
test this hypothesis, we examined the effect of heat exposure on nucleases. In the absence
of hyperthermia, incubation of the TDP2 substrate with cell lysates for a prolonged 90 min
period led to degradation of the 5′P-tyr and 5′P bands. In contrast, prior exposure of
cells to 43 ◦C led to a remarkable protection from degradation (Figure 4a). These results
suggest that the nuclease activities are reduced during heat stress. Since TDP2 produces
directly ligatable ends that require no further processing [41], we incubated the products
of TDP2 reaction with a complementary DNA duplex substrate and T4 DNA ligase to
monitor full repair products (Figure 4b,c). Only one hour exposure to 43 ◦C increased the
amount of full repair products ~5-fold, while five hours increased it ~15-fold (Figure 4d).
Notably, TDP2+/+ and TDP2-/- cells used in this study have been previously employed to
show lack of full ligation in the absence of TDP2 because nuclease processing produces
nonligatable DNA termini [41]. As expected, supplementing the reaction with exogenous
nucleases reversed the protective effect of hyperthermia (Supplementary Figure S3a). The
increased formation of full reaction products by heat exposure could either be due to
increased TDP2 activity or inhibition of nuclease activities. The former is unlikely as we
showed that hyperthermia suppresses TDP2 level and activity (Figure 2a,b). Thus, these
observations suggest that although hyperthermia inhibits the activity of both TDP2 and
nucleases, the inhibitory effect on nucleases is predominant, thereby favoring a TDP2 error-
free repair. Furthermore, these observations show that nucleases contribute to the DNA
damage induced following TOP poisoning and that hyperthermia inhibits this nonspecific
degradation by suppressing the nuclease activity, which may explain the reduction in the
extent of DNA damage quantified in Figure 3.









Figure 4. Hyperthermia inhibits nonspecific nucleases and channels the damage to TDP2-mediated error-free repair.
(a) RKO cells were incubated for the indicated time at 43 ◦C. Then, cells were collected and lysed. Whole cell lysates (15 µg)
were incubated with TDP2 substrate for 1.5 h to monitor TDP2 catalytic activity. Reaction products were separated by
20% denaturing PAGE. TDP2 catalytic activity was quantified as % cleavage of 5′P-Tyr to 5′P. (b) Schematic representation
for the in vitro reaction and the substrates that were used in panel (c). (c) RKO cells were treated with hyperthermia at
43 ◦C for the indicated time, and then the cells were collected, and lysed. The whole cell lysates were incubated with TDP2
substrate in the presence or absence of complementary substrate, and T4 ligase. (d) Quantification of the fold increase in
the error-free repair in (c). Data are the average of at least three biological replicates ± STD. Asterisks denote statistical
significance (** p < 0.01 and *** p < 0.001; Student’s t-test).
We next examined the effect of hyperthermia on TDP1 substrate degradation. TDP1
activity is metal ion independent, and TDP1 reaction is free from Mg2+ but contains the
chelating agent, EDTA. The absence of metal ions in the TDP1 reaction renders nucleases
and PNKP inactive. To examine nuclease activity, we incubated the TDP1 substrate with
TK6 cell lysates and compared reaction products in the presence of EDTA or Mg2+. Heat
exposure did not impact the products of TDP1 catalytic activity when reactions were
performed in the presence of EDTA (Figure 5a, left). In contrast, performing the reactions in
the presence of Mg2+ led to a reduction in the products of TDP1 activity, which was reversed
by heat exposure in a time-dependent manner. Again, only 1 h exposure to hyperthermia
led to a significant accumulation of TDP1 products, compared to control cells that were
not exposed to hyperthermia (Figure 5a, right). These observations were not cell-type
specific as they were also observed with lysates prepared from RKO cells (Supplementary
Figure S3b). To test if nucleases degrade the TDP1 substrate (3′-PY) or products (3′-P),
we compared lysates from wild-type and TDP1 knockout TK6 cells. Both TDP1 substrate
and reaction products were prone to concentration-dependent nucleolytic degradation
(Figure 5b, top). Heat exposure, however, led to significant protection, increasing TDP1
reaction products (Figure 5b, bottom).
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Figure 5. Hyperthermia inhibits nonspecific nucleases and channels the damage to TDP1-mediated error-free repair.
(a) TK6TDP1+/+ cells were treated with hyperthermia at 43 ◦C for the indicated time. Then, the cells were collected and lysed.
Whole cell lysates (2.5 µg) were incubated with TDP1 substrate (presented in Figure 2a) for 1 h to monitor TDP1 catalytic
activity in buffer containing EDTA or Mg2+. Reaction products were separated by 20% denaturing PAGE. The intensity of
TDP1-product bands was normalized to 0 h-EDTA sample and presented as percentage change. (b) Increased concentration
of cell lysates (2.5, 5, and 7.5 µg) from TK6TDP1+/+ and TK6TDP1-/- cells were incubated with TDP1 substrate for 1 h in buffer
containing Mg+2 to assess TDP1 activity as in (a). TK6TDP1+/+ cells were incubated at 37 or 43 ◦C for 5 h. Then, increased
concentration of whole cell lysates (2.5, 5, and 7.5 µg) from each group were incubated with TDP1 substrate to assess TDP1
activity as in (a). (c) TK6TDP1+/+ cells were treated with hyperthermia at 43 ◦C for the indicated time, and then the cells
were collected and lysed. The whole cell lysates were incubated with TDP1 substrate in the presence or absence of alkaline
phosphatase (ALP). (d) Model for the in vitro reaction and substrates that were used in panel (e). (e) TK6TDP1+/+ cells were
treated with hyperthermia at 43 ◦C for the indicated time, and then the cells were collected and lysed. The whole cell lysates
were incubated with TDP1 substrate either in the presence or absence of complementary substrate, T4 PNK and T4 DNA
ligase. (f) Quantification of the fold increase in the error-free repair in (e). (g) G1 synchronized TK6TDP1+/+ and TK6TDP1-/-
cells were either treated with 100 µM CPT in normal media, or media supplemented with 5 g/L EDTA or 5 g/L sodium
citrate for 45 min. The cells were collected and processed by the neutral comet assays. Mean tail moments were quantified
for 100 cells per sample per experiment. Data are the average of at least three biological replicates ± SD. Asterisks denote
statistical significance (* p < 0.05, ** p < 0.01 and *** p < 0.001; Student’s t-test).
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Unlike TDP2, TDP1 reaction produces 3′-P termini that require phosphatase activity
before ligation. To confirm the protective effect of hyperthermia on TDP1 reaction products,
we supplemented the reactions with alkaline phosphatase, which converts 3′P to 3′OH
termini, resulting in a slower migrating band on denaturing gels. Heat exposure led
to a time-dependent increase in 3′-OH termini, which further reinforces the protective
effect of hyperthermia from nucleolytic degradation (Figure 5c). Next, we measured full
ligation by incubating lysates with the TDP1 substrate in the presence of a complementary
duplex substrate, PNK, and ligase. Here again, the formation of complete reaction products,
indicative of error-free complete repair, was increased by heat exposure in a time-dependent
manner, and the results were significant after only 1 h of heat exposure (Figure 5d–f). If
what we observed in vitro is also true in cells, then removing metal ions from cell culture
media should also suppress TOP1 mediated DNA strand breaks in both the wild-type and
TDP1 knockout cells reminiscent to heat exposure in Figure 3a,b. Indeed, adding EDTA or
sodium citrate to the culture media reduced CPT-induced DNA strand breaks (Figure 5g).
We noted that the effect of metal chelators was not as strong as heating, which could be
dependent on the concentration, time, or the specificity of the chelators. Taken together,
we conclude that hyperthermia inhibits nuclease activity, which has two consequences;
(1) preventing the nonspecific processing of TOP-induced DNA damage, which reduces the
overall quantity of DNA damage (Figure 3), and (2) channeling the repair of the remaining
TOP-induced DNA damage to the TDP pathway (Figures 4 and 5).
2.4. Hyperthermia Reduces Topoisomerase-Induced Genomic Instability and Inflammation
The physiological implication of these findings is that hyperthermia favors error-free
repair and consequently suppresses hallmarks of genomic instability driven by error-prone
nucleases [37–43]. To test this, we took advantage of the reported TOP2-induced chro-
mosomal translocation models. We used an established protocol to induce chromosomal
translocation in the prostate cancer cell line, LNCaP [62]. Hormonally deprived LNCaP
cells were treated with etoposide and dihydrotestosterone (DHT) to induce chromosomal
translocations, measured by qPCR. Strikingly, heat exposure suppressed TOP2-induced
translocations (Figure 6a). Another hallmark of genomic instability is the formation of
micronuclei (MN). Here again, heat exposure suppressed the level of etoposide-induced
micronuclei from 11.1 MN/100 cells at 37 ◦C to 8.3 MN/100 cells at 43 ◦C, ~25% reduc-
tion (Figure 6b, left). Notably, the protective effect of hyperthermia on micronuclei was
TDP2-dependent, since hyperthermia failed to exert a protective effect in cells lacking
TDP2 (Figure 6b, right). Micronuclei are not only a marker of genomic instability but also
responsible for DNA damage-induced inflammation. Cyclic GMP-AMP synthase (cGAS)
localizes to micronuclei and generates the cyclic dinucleotide cyclic GMP-AMP (cGAMP),
which induces a type I interferon response via the adaptor STING, a stimulator of inter-
feron genes [63,64]. Consistent with this, hyperthermia suppressed the etoposide-induced
expression of interferon-stimulated genes IFIT1, IFIT3, and CCL5, which lasted for 72 h
post-treatment (Figure 6c). Taken together, we conclude that high temperature protects
from TOP2-induced genomic instability and inflammation.
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Figure 6. Hyperthermia reduces the level of topoisomerase-induced DNA damage, genomic instability and inflammation.
(a) LNCaP cells were hormonally starved for 48 h before treatment with hyperthermia at 43 ◦C for 1.5 h, and then with
100 nM DHT and 100 µM Etoposide (ETO) for 24 h. After treatment, the cells were reincubated for 24 h in fresh media
before being harvested. The gene fusion of TMPRSS2:ERG was examined by qPCR. (b) MEFTDP2+/+ and MFETDP2-/- cells
were treated with DMSO, preheated at 43 ◦C and/or 15 µM ETO for 1 h, and then cells were synchronized by cytochalasin
B for 24 h. After fixation and DAPI staining, the micronuclei (indicated by arrows) were counted in binucleated cells only.
(c) MEFTDP2+/+ cells were treated with DMSO, preheated at 43 ◦C and/or 30 µM ETO for 2.5 h. The RNA was isolated after
48 or 72 h and the level of CCL5, IFIT1, and IFIT2 were assessed by qPCR. Data are the average of at least three biological
replicates ± SD. Asterisks denote statistical significance (* p < 0.05, and ** p < 0.01; Student’s t-test).
3. Discussion
Similar to other repair pathways examined to date, we show that the activity of
TDP1 and TDP2 is compromised following heat stress. We further show that hyperther-
mia exhibits a more pronounced effect in inhibiting cellular nucleases, thereby sparing
the error-prone removal of TOPcc by nucleases for an error-free repair by TDPs. This
leads to suppression of TOP-induced genomic instability, which is consistent with the
inverse correlation between cancer incidence and annual temperature in humans [2,3] and
mice [65].
Despite their importance, how cells control nuclease activities to prevent detrimental
genomic degradation remains unclear [66,67]. Growing evidence suggests that bypassing
nuclease activities holds a higher degree of complexity than initially thought. It involves
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a tight regulation between signaling and repair pathways [68–71]. Here, we propose a
different layer of regulation driven by heat exposure as a physical regulator of the cellular
nuclease activity, which results in the suppression of topoisomerase-induced DNA damage
and genomic instability.
First, we examined the effect of hyperthermia on TDP1 and TDP2 catalytic activities
to explain the antagonistic effect between hyperthermia and topoisomerase inhibitors. We
showed that TDPs activity was compromised during heat stress. Paradoxically, and only in
the presence of metal ions, hyperthermia increased TDP repair products (3′P in the case
of TDP1 and 5′P in the case of TDP2). Through a series of biochemical experiments, we
showed that this effect was due to hyperthermia-induced inhibition of nucleases. Nuclease
inhibition by hyperthermia renders the remaining activity of TDP capable of taking over
DNA repair events. Thus, hyperthermia spares the error-prone removal of TOPcc by





Figure 7. Model for the repair of topoisomerase induced damage in physiological temperature and heat stress. The cell
at the normal physiological temperature (37 ◦C) can employ redundant pathways to remove the trapped topoisomerase.
The first pathway is mediated by TDPs enzymes which hydrolyze the tyrosine bond between the topoisomerase and DNA,
leading to the removal of the DNA–protein crosslink in error free mode. The second pathway is mediated by specific
nucleases (CtIP, MRN, XPF, and MUS81) that nucleolytically cut the DNA, releasing the topoisomerase and a fragment
of DNA. This pathway leads to the formation of breaks that can be further repaired by either homologous recombination
(HR) or non-homologous end joining (NHEJ) in error free or error prone mode, respectively. The third pathway is cytotoxic
and does not lead to the repair of the damage. The cell has an army of nonspecific nucleases. Their toxic involvement can
further process the damaged sites leading to the formation of more damage and inducing cell death. Under heat stress, the
cell inhibits the nucleases, so it can only depend on TDPs to repair the topoisomerase-induced damage leading to delayed
error free repair.
Several classes of nucleases are metal ion-dependent, and the Mg2+ ion is most fre-
quently associated with nucleases due to its abundance, solubility and redox stability [67].
Measuring the topoisomerase-induced DNA damage in the presence of chelators such as
EDTA or sodium citrate further confirmed this hypothesis. Prior incubation with chela-
tors reduced the CPT-induced DNA strand breaks similar to hyperthermia. Nonetheless,
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the current topoisomerase-induced toxicity model relies on the generation of cytotoxic
DSBs. DSBs generation can be either direct due to TOPcc collision with replication forks
or indirect as a consequence of accumulating positive supercoiling ahead of replication
forks due to the inhibition of topoisomerase activity [37,38,49,72]. Our findings suggest
that topoisomerase inhibitors induce cytotoxicity through nonspecific processing of TOP-
DNA breaks by nucleases. Moreover, several reports suggested that the error-prone
repair of topoisomerase-induced DNA breaks lead to the development of many forms of
cancer [37,41–43,49,51–54]. Our findings suggest that hyperthermia protects from TOP-
induced genomic instability by reducing the quantity of DNA damage and by favoring
an error-free repair. Hyperthermia effectively shielded the DNA from etoposide-induced
chromosomal translocations in a prostate cancer model and suppressed the formation of
etoposide-induced micronuclei and inflammation.
Why nucleases are more labile to hyperthermia than other proteins such as TDPs is
unclear. How the repair of TOPcc is regulated in disorders with impaired thermoregu-
latory autonomic pathways will be exciting to explore [7]. Furthermore, our model has
implications for viral infections. The infection-induced fever may increase viral load in the
host by inhibiting the nucleases, giving the virus a chance to replicate its genome using
TDP2, which has been shown to facilitate viral replication [73,74].
In summary, we show that high temperature impacts topoisomerase-induced DNA
damage by: (1) reducing the extent of DNA strand breaks by inhibiting the nucleases
and (2) enhancing the quality of repair of the remaining damage by a more pronounced
inhibitory effect on nucleases, favoring the TDP error-free pathways. These findings
may help to explain the inverse relationship between environmental temperature and the
geographical distribution of cancer and could be exploited in the applications of controlled
heat as an adjunct to topoisomerase targeting therapeutics.
4. Methodology
4.1. Cell Culture, Synchronization, and Hyperthermia Treatment
Colorectal cancer cell line, RKO, lymphoblast cell lines, TK6TDP1+/+ and TK6TDP1-/-,
and prostate cancer cell line, LNCaP, were cultured in standard RPMI-1640 media (Lonza,
USA). Transformed mouse embryonic fibroblasts MEFTDP2+/+, MFETDP2-/-, and breast
cancer cell line, MCF-7 were cultured in DMEM media (Lonza, USA). Both media were
supplemented with 10% FBS (Sigma, USA) and 1% penicillin/streptomycin (Lonza, USA).
The cells were maintained at 37 ◦C in 5% CO2 incubator. For cellular synchronization
double-thymidine block was used by treatment with 2 mM thymidine for 16 h, then released
for 6 h in fresh media, and finally treated with thymidine for another 16 h. Hyperthermia
treatment was applied by maintaining cells at 37, 43, or 45 ◦C in CO2 incubators (for long
term treatment) or water bath (short term treatment). All cell lines were obtained from the
University of Sheffield (El-Khamisy lab) and routinely tested negative for mycoplasma.
4.2. Comet Assays
Alkaline comet assay measures SSBs and DSBs, whereas neutral comet assays measure
DSBs. After different treatments, cells were collected, washed by cold PBS and suspended
in PBS. Equal volume of 1.3% low melting agarose (Type VII, Sigma, USA) was added to
the cells. The mixture was layered onto prechilled frosted glass slides (Fisher Scientific,
USA), pre-coated with 0.6% agarose. For alkaline comet assays, lysis buffer (2.5 M NaCl,
10 mM Tris-HCl pH 7, 100 mM EDTA, 1% Triton X-100, 10% DMSO, pH 10) was added on
the slides for 1 h at 4 ◦C. Electrophoresis was performed in 50 mM NaOH and 1 mM EDTA
at 25 V for 30 min. For neutral assays, lysis buffer (2.5 M NaCl, 10 mM Tris-HCl pH 7, 0.1 M
EDTA, 0.5% Triton X-100, 3% DMSO, 1% N-lauroylsarcosine, pH 9.5) was added for 90 min
at 4 ◦C, and electrophoresis was performed in 0.3 M sodium acetate, and 100 mM Tris-HCl
for 1 h. The samples were neutralized in 400 mM Tris-HCl pH 7, and DNA was stained with
SYBR Green I (1:10,000, in PBS) for 10 min. Average tail moments from at least 100 cells for
each sample were detected using Comet Assay IV software (Perceptive Instruments, UK).
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Data were presented as an average ± SD from three independent experiments. Statistical
analysis was performed using Student’s t-test.
4.3. Cell Lysate Preparation
After treatment, the cells were collected and lysed in lysis buffer (40 mM tris-HCL
PH 7.5, 1% Triton X-100, 100 mM NaCl, 1 mM DTT, 10% sigma protease inhibitor cocktail).
Total protein concentration was determined using the Bradford assay. The whole-cell lysate
was kept at −80 ◦C.
4.4. TDPs Activity Assay
The in vitro 3′-tyrosyl-DNA phosphodiesterase and 5′-tyrosyl-DNA phosphodiesterase
activities were determined using a gel-based assay. Biochemical assays were performed in
10 µL reaction volumes containing TDP1 reaction buffer (50 mM Tris HCL pH 7.5, 50 mM
KCl, 1 mM DTT, 100 µg/mL BSA, and 10 M EDTA or 1 mM MgCL2) or TDP2 reaction
buffer (50 mM Tris HCL pH 7.5, 50 mM KCl, 1 mM DTT, 100 µg/mL BSA, and 1 mM
MgCl2), cell lysate, and 6 nM Cy5.5-labelled substrate oligomer. TDP1 substrate 5′Cy5.5-
GATCTAAAAGACT (3′P-Tyr) (Midland Certified Reagent Company, USA) was used to
determine TDP1 catalytic activity. Only in the ligation experiments, the TDP1 substrate was
annealed to 5′-GATGAGTCTTTTAGATC-3′, and both are ligated to the annealed comple-
mentary (5′-ATGGTAGGCAAC-3′ and 5′-CATCGTTGCCTACCAT-3′). For TDP2 reaction,
5′(P-Tyr) CATCGTTGCCTACCAT (Cy5.5)-3′ (Midland Certified Reagent Company, USA)
complemented to 5′-ATGGTAGGCAAC-3′ to form 4 nucleotide overhang was used. In
case of the ligation reaction, this complement was ligated to the annealed complement of
(5′-GATCTAAAAGACT-3′, and 5′-GATGAGTCTTTTAGATC-3′). The reactions progressed
at 37 ◦C for 30–90 min and were quenched with 10 µL loading buffer (44% deionized
formamide, 2.25 mM Tris-borate, 0.05 mM EDTA, and 1% bromophenol blue). Samples
were then heated at 90 ◦C for 5 min before separation on a 20% urea SequaGel (Geneflow,
UK) at 150 V. Reaction products were visualized by gel imaging using ChemiDoc™ MP
Imaging System (Bio-Rad, USA).
4.5. Western Blot
After treatment, cells were washed, collected and lysed in RIPA buffer. After that,
equal amounts of total protein were boiled with SDS-polyacrylamide gel electrophoresis
(PAGE) sample buffer at 95 ◦C for 5 min and 40–90 µg of protein was loaded for separation
by 12% SDS-PAGE. Electrophoresed proteins were then transferred onto PVDF membranes
(Millipore, USA) either using semidry (turbo, Bio-Rad, USA) or wet transfer. The mem-
branes faced blocking in 5% non-fat milk for 1 h. Then, the membranes were incubated with
primary antibodies; anti-TDP1 (Santa Cruz, USA, SC-365674), anti-TDP2 (Santa Cruz, USA,
SC-377280), anti-UCHL3 (Thermo Fisher, MA517230) overnight at 4 ◦C or anti-GAPDH
(Abcam, ab37168) for 1 h at room temperature. After three washes in T-PBS (3 × 5 min),
membranes were then incubated with anti-mouse horseradish peroxidase-linked IgG anti-
body (Thermo Fisher Scientific, USA) for 1 h at room temperature. After 3 × 5 min washes
in T-PBS, visualization was performed by enhanced chemiluminescence (ECL) detection
reagent (Amersham ECL Reagent, GE, USA). Imaging was performed by ChemiDoc™ MP
(Bio-Rad, USA). The raw uncropped images wre included in supplementary Figure S4.
4.6. Viability
TK6TDP1+/+, and TK6TDP1-/- cells (5000 cells/well) were treated with CPT at varying
concentrations in triplicate after hyperthermia treatment. On day three, 20 µL cell-titer blue
(Promega, USA) was added, and the plate was incubated at 37 ◦C. After 4 h, the viability
was quantified as fluorescence intensity using a microplate reader, FLUOstar Omega (BMG
LABTECH). In the case of MEFTDP2+/+ and MFETDP2-/- cells (5000 cells/well) were treated
with varying etoposide concentrations after hyperthermia treatment. On day 5, cell-titer
blue (Promega, USA) was added, and the viability was measured.
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4.7. TOP1 Activity Assay
DNA topoisomerase I activity was assayed by the relaxation of negatively supercoiled
plasmid DNA as described previously [75]. The reaction was done in a total volume of
20 µL containing 50 mM Tris-HCl, pH 7.5, 100 mM KCl, 1 mM DTT, 10 mM EDTA, 5 µg/mL
BSA, and 200 ng of supercoiled pEGFPN1 plasmid. After incubation at 37 ◦C for 30 min,
the reactions were stopped by adding 5 µL of loading dye (50 mM EDTA, 50% glycerol,
and 0.5% bromophenol blue). The DNA was electrophoresed in a 1% agarose gel with TAE
buffer (50 mM Tris–HCl, pH 8.0, and 2 mM EDTA). The gels were visualized under UV
illumination after being stained with ethidium bromide.
4.8. Quantitative PCR
Cells were washed and collected for RNA extraction after each treatment according
to the manufacturer’s instructions (RNeasy Mini Kit; Qiagen, Germany). High-Capacity
cDNA Reverse Transcription Kit (Thermo Fisher Scientific, USA) was used to prepare
the cDNA. The qPCR (QuantStudio 12K Flex Real-Time PCR System, Thermo Scientific,
USA) was performed using SYBR Green Master Mix (Thermo Fisher Scientific, USA) and
the following primers: TDP1 F: 5′-CAGAGTTCAGGAAGAAGCCAATC-3′; TDP1 R: 5′-
GCATCATTTTCGTGTGGTGTGTTC-3′; TDP2 F: 5′-AGCCCAAGACCTATGTTGACC-3′;
TDP2 R: 5′-CTAAGTAGGAACACACCCCTC-3′; GAPDH F: 5′-TTCGTCATGGGTGTGAA-
CCA-3′; GAPDH R: 5′-TGATGGCATGGACTGTGGTC-3′; mouse IFIT1 F: 5′-TCTAAACAG-
GGCCTTGCAG-3’; mouse IFIT1 R: 5′-GCAGAGCCCTTTTTGATAATGT-3’; mouse IFIT3
F: 5′-TGAACTGCTCAGCCCACA-3′; mouse IFIT3 R: 5′-TCCCGGTTGACCTCACTC-3’;
mouse CCL5 F: 5′-ACGTCAAGGAGTATTTCTACAC-3′; mouse CCL5 R: 5′-GATGTATTC-
TTGAACCCACT-3′; mouse GAPDH F: 5′-AACTTTGGCATTGTGGAAGG-3′; mouse GAP-
DH R: 5′-ACACATTGGGGGTAGGAACA-3′.
4.9. Chromosomal Translocation Assay
We adapted a published technique for the induction of chromosomal translocation in a
prostate cancer cell line [62]. Briefly, LNCaP cells were starved in phenol-free DMEM
(Lonza, USA) supplemented with 5% charcoal-stripped fetal bovine serum (Biowest,
France) before treatment with hyperthermia at 43 ◦C for 1.5 h, and then with 100 nM
dihydrotestosterone (DHT) and 100µM etoposide for 24 h. After treatment, the cells were
reincubated for 24 h in fresh media before being harvested. Cells were then collected for
RNA extraction according to the manufacturer’s instructions (RNeasy Mini Kit; Qiagen,
Qiagen, Germany). High-Capacity cDNA Reverse Transcription Kit (Thermo Fisher Sci-
entific, USA) was used to prepare the cDNA. The gene fusion events of TMPRSS2:ERG
were examined by qPCR (QuantStudio 12K Flex Real-Time PCR System, Thermo Scien-
tific) using SYBR Green Master Mix (Thermo Fisher Scientific, USA). Relative quantities of
TMPRSS2:ERG fusion transcript was normalized to GAPDH and the expression level of TM-
PRSS2. The relative amount of each fusion transcript was then calibrated to the DHT sample.
The used primers are TMPRSS2 F: 5′-CTGGTGGCTGATAGGGGAT-3′; TMPRSS2 R: 5′-
GTCTGCCCTCATTTGTCGAT-3′; TMPRSS2-ERG F: 5′-AGCGCGGCAGGTTATTCCA-3′;
TMPRSS2-ERG R: 5′-ATCATGTCCTTCAGTAAGCCA-3′.
4.10. Micronuclei
Micronuclei were analyzed in transformed MEFs previously seeded onto coverslips.
Following treatment, cytochalasin B was added at 4 mg/mL. After 24 h, cells were fixed,
stained with DAPI, and images were acquired by IN Cell Analyzer 2200 (GE Healthcare
Life Sciences, USA). Only binucleated cells were scored.
4.11. Immunoprecipitation and Nano-LC MS/MS Analysis
TK6 cells were mock-treated or treated with 10 µM MG132 and/or heated at 43 ◦C
for 1.5 h. Cells were washed with cold PBS, lysed on ice in RIPA lysis buffer (50 mM Tris,
pH 7, 150 mM NaCl, 0.5% sodium deoxycholate and 1% NP-40) supplemented with a
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protease inhibitor cocktail (Sigma, USA) for 1 h, and then centrifuged at 15,000 rpm for
10 min. The supernatant was mixed with protein A/G-Sepharose mix (Santa Cruze, USA),
preswelled in PBS and precoated with anti-human TDP1 antibodies by gently shaking
for 1 h at 40 ◦C and centrifuged for 1 min at 3000 rpm. After washing with lysis buffer,
the immunocomplex was washed three times with lysis buffer. TDP1 immunoprecipitate
were subjected to protein digestion and stage tipping as described [76]. Nano-LC MS/MS
analysis was carried out using TripleTOF 5600 + (AB Sciex, Canada) interfaced at the front
end with Eksigent nanoLC 400 auto-sampler with Ekspert nanoLC 425 pump. CHROMXP
C18CL 5 µm (10 × 0.5 mm) (Sciex, Germany). Column was used to trap the peptides
in trap and elute mode. The MS and MS/MS ranges were 400–1250 and 170–1500 m/z,
respectively. A 55 min linear gradient of 3–40% solution B (80% ACN, 0.2% formic acid)
was applied. Data-dependent acquisition (DDA) mode with a charge state of 2–5 was used
to select the 40 most intense ions sequentially [76]. MS/MS spectra were searched using X
Tandem in Peptide shaker (version 1.16.26) against Homo Spaiens (Taxon identifier: 9606)
UniProtKB/TrEMBL database (213,287 entries) with reversed decoy sequences and FDR
of 1%. Biomart was used to map the UniProtKB Gene Name ID to gene names and gene
description [77,78]. IDs that were not identified via Biomart were manually added.
5. Conclusions
Hyperthermia enhances the anticancer effects of radiotherapy and multiple chemother-
apeutics. In a remarkable contrast, hyperthermia protects cells from topoisomerase-
targeting therapeutics through an unknown mechanism. Here, we report that hyperthermia
inhibits the error-prone nucleases and the error-free TDPs pathways. The inhibitory effect
of hyperthermia is more pronounced on nucleases, thereby favoring repair by the error-free
TDP pathways, which reduces hallmarks of therapy-associated chromosomal instability.
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M.; McEwan, A.; et al. CRISPR screens identify genomic ribonucleotides as a source of PARP-trapping lesions. Nature 2018, 559,
285–289. [CrossRef]
59. Liao, C.; Beveridge, R.; Hudson, J.J.; Parker, J.D.; Chiang, S.-C.; Ray, S.; Ashour, M.E.; Sudbery, I.; Dickman, M.J.; El-Khamisy,
S.F. UCHL3 Regulates Topoisomerase-Induced Chromosomal Break Repair by Controlling TDP1 Proteostasis. Cell Rep. 2018, 23,
3352–3365. [CrossRef]
60. Hudson, J.J.; Chiang, S.-C.; Wells, O.S.; Rookyard, C.; El-Khamisy, S.F. SUMO modification of the neuroprotective protein TDP1
facilitates chromosomal single-strand break repair. Nat. Commun. 2012, 3, 1–13. [CrossRef]
61. Velichko, A.K.; Petrova, N.V.; Razin, S.V.; Kantidze, O.L. Mechanism of heat stress-induced cellular senescence elucidates the
exclusive vulnerability of early S-phase cells to mild genotoxic stress. Nucleic Acids Res. 2015, 43, 6309–6320. [CrossRef]
62. Jin, C.; Yang, L.; Xie, M.; Lin, C.; Merkurjev, D.; Yang, J.C.; Tanasa, B.; Oh, S.; Zhang, J.; Ohgi, K.A.; et al. Chem-seq permits
identification of genomic targets of drugs against androgen receptor regulation selected by functional phenotypic screens. Proc.
Natl. Acad. Sci. USA 2014, 111, 9235–9240. [CrossRef]
63. Harding, S.M.; Benci, J.L.; Irianto, J.; Discher, D.E.; Minn, A.J.; Greenberg, R.A. Mitotic progression following DNA damage
enables pattern recognition within micronuclei. Nature 2017, 548, 466–470. [CrossRef] [PubMed]
64. MacKenzie, K.J.; Carroll, P.; Martin, C.-A.; Murina, O.; Fluteau, A.; Simpson, D.J.; Olova, N.; Sutcliffe, H.; Rainger, J.K.; Leitch,
A.; et al. cGAS surveillance of micronuclei links genome instability to innate immunity. Nature 2017, 548, 461–465. [CrossRef]
[PubMed]
65. Kokolus, K.M.; Capitano, M.L.; Lee, C.-T.; Eng, J.W.-L.; Waight, J.D.; Hylander, B.L.; Sexton, S.; Hong, C.-C.; Gordon, C.J.; Abrams,
S.I.; et al. Baseline tumor growth and immune control in laboratory mice are significantly influenced by subthermoneutral
housing temperature. Proc. Natl. Acad. Sci. USA 2013, 110, 20176–20181. [CrossRef]
66. Marti, T.M.; Fleck, O. DNA repair nucleases. Cell. Mol. Life Sci. 2004, 61, 336–354. [CrossRef]
67. Yang, W. Nucleases: Diversity of structure, function and mechanism. Q. Rev. Biophys. 2010, 44, 1–93. [CrossRef] [PubMed]
68. Higgs, M.R.; Stewart, G.S. Protection or resection: BOD1L as a novel replication fork protection factor. Nucleus 2016, 7, 34–40.
[CrossRef]
69. Ashour, M.E.; Mosammaparast, N. Mechanisms of damage tolerance and repair during DNA replication. Nucleic Acids Res. 2021,
49, 3033–3047. [CrossRef]
70. Abe, T.; Kawasumi, R.; Giannattasio, M.; Dusi, S.; Yoshimoto, Y.; Miyata, K.; Umemura, K.; Hirota, K.; Branzei, D. AND-1 fork
protection function prevents fork resection and is essential for proliferation. Nat. Commun. 2018, 9, 1–13. [CrossRef]
71. Rickman, K.; Smogorzewska, A. Advances in understanding DNA processing and protection at stalled replication forks. J. Cell
Biol. 2019, 218, 1096–1107. [CrossRef]
72. Koster, D.A.; Palle, K.; Bot, E.S.M.; Bjornsti, M.-A.; Dekker, N.H. Antitumour drugs impede DNA uncoiling by topoisomerase I.
Nat. Cell Biol. 2007, 448, 213–217. [CrossRef] [PubMed]
73. Virgen-Slane, R.; Rozovics, J.M.; Fitzgerald, K.D.; Ngo, T.; Chou, W.; Noort, G.J.V.D.H.V.; Filippov, D.V.; Gershon, P.D.; Semler,
B.L. An RNA virus hijacks an incognito function of a DNA repair enzyme. Proc. Natl. Acad. Sci. USA 2012, 109, 14634–14639.
[CrossRef] [PubMed]
74. Königer, C.; Wingert, I.; Marsmann, M.; Rösler, C.; Beck, J.; Nassal, M. Involvement of the host DNA-repair enzyme TDP2 in
formation of the covalently closed circular DNA persistence reservoir of hepatitis B viruses. Proc. Natl. Acad. Sci. USA 2014, 111,
E4244–E4253. [CrossRef] [PubMed]
75. Nitiss, J.L.; Nitiss, K.C. Tdp2: A Means to Fixing the Ends. PLoS Genet. 2013, 9, e1003370. [CrossRef]
76. Rappsilber, J.; Mann, M.; Ishihama, Y. Protocol for micro-purification, enrichment, pre-fractionation and storage of peptides for
proteomics using StageTips. Nat. Protoc. 2007. [CrossRef] [PubMed]
77. Durinck, S.; Spellman, P.T.; Birney, E.; Huber, W. Mapping identifiers for the integration of genomic datasets with the R/
Bioconductor package biomaRt. Nat. Protoc. 2009. [CrossRef] [PubMed]
78. Soudy, M.; Anwar, A.M.; Ahmed, E.A.; Osama, A.; Ezzeldin, S.; Mahgoub, S.; Magdeldin, S. UniprotR: Retrieving and visualizing
protein sequence and functional information from Universal Protein Resource (UniProt knowledgebase). J. Proteom. 2020.
[CrossRef]
